Ocular perfusion pressure and visual field indice modifications induced by α-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration: An acute study on primary open-angle glaucoma patients

Ophthalmologica

Volumn 217, Issue 1, 2003, Pages 39-44

  Costagliola, Ciro ^a   Parmeggiani, Francesco ^a   Ciancaglini, Marco ^b   D'Oronzo, Emanuele ^b   Mastropasqua, Leonardo ^b   Sebastiani, Adolfo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Agonists; Ocular perfusion pressure; Primary open angle glaucoma; Visual field indices

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; APRACLONIDINE; BRIMONIDINE; CLONIDINE; EYE DROPS;

ACUTE DRUG ADMINISTRATION; ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SELECTIVITY; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; OPEN ANGLE GLAUCOMA; PARAMETER; PERFUSION PRESSURE; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; VASOMOTOR REFLEX; VISION; VISUAL FIELD; VISUAL FIELD DEFECT;

ADMINISTRATION, TOPICAL; ADRENERGIC ALPHA-AGONISTS; ADULT; AGED; BLOOD PRESSURE; CLONIDINE; DOUBLE-BLIND METHOD; EYE; FEMALE; GLAUCOMA, OPEN-ANGLE; HEART RATE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; QUINOXALINES; VISUAL FIELDS;

EID: 0037266026     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068249     Document Type: Article

References (30)

1. Wilensky JT: The role of brimonidine in the treatment of open-angle glaucoma. Surv Ophthalmol 1996;41(suppl 1):S3-S8.
2. Isaac L: Clonidine in the central nervous system: Site and mechanism of hypotensive action. J Cardiovasc Pharmacol 1980;2(suppl 1):S5-S19.
3. Krieglstein GK, Langham ME, Leydhecker W: The peripheral and central neural actions of clonidine in normal and glaucomatous eyes. Invest Ophthalmol Vis Sci 1978;17:149-158.
4. Yuksel N, Guler C, Caglar Y, Elibol O: Apraclonidine and clonidine: A comparison of efficacy and side effects in normal and ocular hypertensive volunteers. Int Ophthalmol 1992;16:337-342.
5. Toris CB, Camras CB, Yablonski ME: Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol 1999;128:8-14.
6. Geyer O, Schmidt KG, Pianka P, Neudorfer M, Lazar M: Clonidine provides an allergy-free alternative in glaucoma patients with proven allergy to apraclonidine. Graefes Arch Clin Exp Ophthalmol 2000;238:149-152.
7. Mastropasqua L, Ciancaglini M, Carpineto P, Verdesca G, Ciafre M, Costagliola C: The effect of 1% apraclonidine on visual field parameters in patients with glaucoma and ocular hypertension. Ann Ophthalmol 1998;30:41-45.
8. Burke J, Schwartz M: Preclinical evaluation of brimonidine. Surv Ophthalmol 1996;41(suppl 1):S9-S18.
9. Chien DS, Homsy JJ, Gluchowski C, Tang-Liu DD: Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342, and clonidine in rabbit eyes. Curr Eye Res 1990;9:1051-1059.
10. Robin AL: Short-term effects of unilateral 1% apraclonidine therapy. Arch Ophthalmol 1988;106:912-915.
11. Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K: A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multi-center clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol 1997;115:847-852.
12. Shin DH, Glover BK, Cha SC, Kim YY, Kim C, Nguyen KD: Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy. Am J Ophthalmol 1999;127:511-515.
13. Toris CB, Gleason ML, Camras CB, Yablonski ME: Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995;113:1514-1517.
14. Julius S, Valentini M: Consequences of the increased autonomic nervous drive in hypertension, heart failure and diabetes. Blood Press 1998(suppl 3):5-13.
15. de Champlain J, Karas M, Toal C, Nadeau R, Larochelle P: Effects of antihypertensive therapies on the sympathetic nervous system. Can J Cardiol 1999;15(suppl A):8A-14A.
16. Grassi G, Seravalle G, Stella ML, Turri C, Zanchetti A, Mancia G: Sympathoexcitatory responses to the acute blood pressure fall induced by central and peripheral antihypertensive drugs. Am J Hypertens 2000;13:29-34.
17. Flammer J, Niesel P: Reproducibility of perimetric study results. Klin Monatsbl Augenheilkd 1984;184:374-376.
18. Costagliola C, Iuliano G, Rinaldi M, Russo V, Scibelli G, Mastropasqua L: Effect of topical ketanserin administration on intraocular pressure. Br J Ophthalmol 1993;77:344-348.
19. Johnson CA: Standardizing the measurement of visual field for clinical research. Ophthalmology 1996;103:186-189.
20. Robin AL, Burnstein Y: Selectivity of site of action and systemic effects of topical alpha agonists. Curr Opin Ophthalmol 1998;9:30-33.
21. Aldoori MI, Marmion VJ, Baird RN: Vascular resistance in primary open-angle glaucoma. Acta Ophthalmol Scand 1998;76:668-670.
22. Duijm HF, Berg TJ, Greve EL: Central and peripheral arteriovenous passage times of the retina in glaucoma. Exp Eye Res 1999;69:145-153.
23. Marquardt R, Pillunat LE, Stodtmeister R: Ocular hemodynamics following local administration of clonidine. Klin Monatsbl Augenheilkd 1988;193:637-641.
24. Carlsen JO, Zabriskie NA, Kwon YH, Barbe ME, Scott WE: Apparent central nervous system depression in infants after the use of topical brimonidine. Am J Ophthalmol 1999;128:255-256.
25. Abrams DA, Robin AL, Pollack IP, de Faller JM, De Santis L: The safety and efficacy of topical 1% ALO 2145 (p-aminoclonidine monohydrochloride) in normal volunteers. Arch Ophthalmol 1987;105:1205-1207.
26. Jampel HD, Robin AL, Quigley HA, Pollack IP: Apraclonidine hydrochloride: A one-week dose-response study. Arch Ophthalmol 1988;106:1069-1073.
27. 2-adrenoceptor activity. Bioorg Med Chem (Lett) 1995;5:1745-1750.
28. Mastropasqua L, Ciancaglini M, Carpineto P, Zuppardi E, Falconio G, Gallenga PE: Effects of brimonidine 0.2% on blue-yellow perimetry of glaucomatous patients. Acta Ophthalmol Scand Suppl 1998;227:36.
29. Carlsson AM, Chauhan BC, Lee AA, LeBlanc RP: The effect of brimonidine tartrate on the retinal blood flow in patients with ocular hypertension. Am J Ophthalmol 2000;129:297-301.
30. Hayreh SS: Blood supply of the anterior optic nerve; in Ritch R, Shields MB, Krupin T (eds): The Glaucomas. St Louis, Mosby, 1989, pp 133-161.